Literature DB >> 17440091

Proteomic analysis of waldenstrom macroglobulinemia.

Evdoxia Hatjiharissi1, Hai Ngo, Alexey A Leontovich, Xavier Leleu, Michael Timm, Mona Melhem, Diane George, Ganwei Lu, Joanna Ghobrial, Yazan Alsayed, Steven Zeismer, Miguel Cabanela, Alex Nehme, Xiaoying Jia, Anne Sophie Moreau, Steven P Treon, Rafael Fonseca, Morie A Gertz, Kenneth C Anderson, Thomas E Witzig, Irene M Ghobrial.   

Abstract

To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKalpha. Other proteins up-regulated by >1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by >2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440091     DOI: 10.1158/0008-5472.CAN-06-3089

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Molecular pathogenesis of Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Casey Philipsborn; Anne Novak; Lucy Hodge; Stephen Ansell; Rafael Fonseca
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease.

Authors:  Steven E Arnold; Natalia Louneva; Kajia Cao; Li-San Wang; Li-Ying Han; David A Wolk; Selamawit Negash; Sue E Leurgans; Julie A Schneider; Aron S Buchman; Robert S Wilson; David A Bennett
Journal:  Neurobiol Aging       Date:  2012-05-02       Impact factor: 4.673

3.  Mammalian diseases of phosphatidylinositol transfer proteins and their homologs.

Authors:  Aaron H Nile; Vytas A Bankaitis; Aby Grabon
Journal:  Clin Lipidol       Date:  2010-12-01

4.  The actin-cytoskeleton pathway and its potential role in inflammatory bowel disease-associated human colorectal cancer.

Authors:  Ziad Kanaan; Motaz Qadan; Maurice Robert Eichenberger; Susan Galandiuk
Journal:  Genet Test Mol Biomarkers       Date:  2010-06

5.  The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Xiaoying Jia; Judith Runnels; Hai T Ngo; Anne-Sophie Moreau; Mena Farag; Joel A Spencer; Costas M Pitsillides; Evdoxia Hatjiharissi; Aldo Roccaro; Garrett O'Sullivan; Douglas W McMillin; Daisy Moreno; Tanyel Kiziltepe; Ruben Carrasco; Steven P Treon; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial
Journal:  Blood       Date:  2007-08-30       Impact factor: 22.113

6.  microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authors:  Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

7.  The BNIP-2 and Cdc42GAP homology (BCH) domain of p50RhoGAP/Cdc42GAP sequesters RhoA from inactivation by the adjacent GTPase-activating protein domain.

Authors:  Yi Ting Zhou; Li Li Chew; Sheng-cai Lin; Boon Chuan Low
Journal:  Mol Biol Cell       Date:  2010-07-21       Impact factor: 4.138

Review 8.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

9.  Targeting NF-kappaB in Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Jérôme Eeckhoute; Xiaoying Jia; Aldo M Roccaro; Anne-Sophie Moreau; Mena Farag; Antonio Sacco; Hai T Ngo; Judith Runnels; Molly R Melhem; Nicolas Burwick; Abdelkareem Azab; Feda Azab; Zachary Hunter; Evdoxia Hatjiharissi; Daniel R Carrasco; Steven P Treon; Thomas E Witzig; Teru Hideshima; Myles Brown; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

10.  Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Authors:  Aldo M Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.